# C_2005266EN.01000301.xml

| 27.10.2005 | EN | Official Journal of the European Union | C 266/3 |
| --- | --- | --- | --- |

27.10.2005

EN

Official Journal of the European Union

C 266/3

---

Prior notification of a concentration

(Case COMP/M.3928 — Teva/Ivax)

(2005/C 266/03)

(Text with EEA relevance)

| 1. | On 18 October 2005, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Teva Pharmaceutical Industries Limited (‘Teva’, Israel) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Ivax Corporation and its various subsidiaries (together ‘Ivax’, USA) by way of purchase of shares |
| --- | --- |

1.

On 18 October 2005, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Teva Pharmaceutical Industries Limited (‘Teva’, Israel) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Ivax Corporation and its various subsidiaries (together ‘Ivax’, USA) by way of purchase of shares

1

| 2. | The business activities of the undertakings concerned are:






  — | for Teva: development, production and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceuticals ingredients in the U.S. and internationally; |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Teva: development, production and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceuticals ingredients in the U.S. and internationally;

| — | for Ivax: development, manufacturing and marketing of branded and generic pharmaceuticals, active ingredients and veterinary products in the U.S. and internationally. |
| --- | --- |

—

for Ivax: development, manufacturing and marketing of branded and generic pharmaceuticals, active ingredients and veterinary products in the U.S. and internationally.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.3928 — Teva/Ivax, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| BE-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.3928 — Teva/Ivax, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

BE-1049 Brussels

---

(1)  OJ L 24, 29.1.2004, p. 1.

1

---